Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Ariyoshi

Showing results (181-190 of 211) with videos related to

Pageof 22
Sort By:
Nihon Gan Chiryo Gakkai Shi|June 20, 1983
[Human lymphoblast interferon. An effective agent on renal cell carcinoma]Y Ono, S Ohshima, T Fujita, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|October 1, 1992
[Anti-emetic effect and safety of single dose of ondansetron injection in double-blind comparison study with placebo]J Ohta, T Taguchi, H Furue, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|October 1, 1992
[Evaluation of SN-307 (ondansetron), given intravenously in the treatment of nausea and vomiting caused by anticancer drugs including cisplatin--a placebo-controlled, double-blind comparative study]M Ikeda, T Taguchi, K Ota, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 1, 1992
[Examination of anti-emetic effect and safety of multiple intravenous doses of ondansetron in patients receiving nonplatinum anti-cancer drugs]N Nukariya, H Niitani, T Taguchi, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|September 1, 1992
[Examination of inhibitory effect, safety and usefulness of SN-307 (ondansetron) administered orally once daily for 3-5 consecutive days on nausea and emesis associated with non-platinum anti-cancer drugs]M Suminaga, H Furue, T Taguchi, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1992
The use of granulocyte colony-stimulating factor to shorten the interval between cycles of mitomycin C, vindesine, and cisplatin chemotherapy in non-small-cell lung cancerM Takada, M Fukuoka, Y Ariyoshi, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|June 1, 1992
[A phase II clinical study of cis-diammine glycolato platinum, 254-S, for primary lung cancer]K Furuse, M Fukuoka, Y Kurita, et al.
Nihon Gan Chiryo Gakkai Shi|December 20, 1983
[Clinical study of combination chemotherapy with continuously infused peplomycin (PEP), cis-dichlorodiammineplatinum (II) (CDDP) and mitomycin C (MMC) (PPM therapy)]T Goto, I Furuta, A Urata, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 1, 1992
[A phase I study of DWA2114R]Y Ariyoshi, A Wakui, K Hasegawa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2006
Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in JapanY Ohe, Y Ohashi, K Kubota, et al.
Pageof 22

Showing results (181-190 of 211) with videos related to

Sort By:
Pageof 22
Nihon Gan Chiryo Gakkai Shi|June 20, 1983
[Human lymphoblast interferon. An effective agent on renal cell carcinoma]Y Ono, S Ohshima, T Fujita, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|October 1, 1992
[Anti-emetic effect and safety of single dose of ondansetron injection in double-blind comparison study with placebo]J Ohta, T Taguchi, H Furue, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|October 1, 1992
[Evaluation of SN-307 (ondansetron), given intravenously in the treatment of nausea and vomiting caused by anticancer drugs including cisplatin--a placebo-controlled, double-blind comparative study]M Ikeda, T Taguchi, K Ota, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 1, 1992
[Examination of anti-emetic effect and safety of multiple intravenous doses of ondansetron in patients receiving nonplatinum anti-cancer drugs]N Nukariya, H Niitani, T Taguchi, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|September 1, 1992
[Examination of inhibitory effect, safety and usefulness of SN-307 (ondansetron) administered orally once daily for 3-5 consecutive days on nausea and emesis associated with non-platinum anti-cancer drugs]M Suminaga, H Furue, T Taguchi, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1992
The use of granulocyte colony-stimulating factor to shorten the interval between cycles of mitomycin C, vindesine, and cisplatin chemotherapy in non-small-cell lung cancerM Takada, M Fukuoka, Y Ariyoshi, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|June 1, 1992
[A phase II clinical study of cis-diammine glycolato platinum, 254-S, for primary lung cancer]K Furuse, M Fukuoka, Y Kurita, et al.
Nihon Gan Chiryo Gakkai Shi|December 20, 1983
[Clinical study of combination chemotherapy with continuously infused peplomycin (PEP), cis-dichlorodiammineplatinum (II) (CDDP) and mitomycin C (MMC) (PPM therapy)]T Goto, I Furuta, A Urata, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 1, 1992
[A phase I study of DWA2114R]Y Ariyoshi, A Wakui, K Hasegawa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2006
Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in JapanY Ohe, Y Ohashi, K Kubota, et al.
Pageof 22